Hello and welcome to the Zero to Finals podcast.

My name is Tom and in this episode I'm going to be talking to you about myelope proliferative disorders.

And you can find written notes on this topic at zero to finals.com slash myelope proliferative disorders

or in the hematology section of the zero to finals medicine book.

So let's get straight into it.

Milo proliferative disorders involve uncontrolled proliferation of a single type of stem cell.

They're considered a form of cancer occurring in the bone marrow, although they tend to develop

and progress slowly.

They have the potential to transform into acute myeloid leukemia.

The myelop proliferative disorders to remember are primary myelofibrosis,

polycythemia vera, and essential thrombosythemia.

For primary myelofibrosis, the proliferating cell line is the hematopoetic stem cells and the blood findings are low hemoglobin,

a high or low white blood cell count and a high or low platelet count.

For polycythemia vera, the proliferating cell line is the erythroid cells, and the blood finding is a high or raised hemoglobin.

For essential thrombosythemia, the proliferating cell line is the mega-cariocyte line, and the blood finding is a high platelet count.

These conditions are associated with mutations in certain genes, the Jack 2 gene, the MPL gene, and the C-A-L-R gene.

The Tom tip for you, the mutation to remember is Jack 2.

Treatment might involve Jack 2 inhibitors such as roxolitinib.

So let's talk in more detail about myelofibrosis.

Milofibrosis can result from primary myelofibrosis. Milofibrosis can result from primary myelofibrosis, polycythemia vera, or essential thrombosythemia.

Milofibrosis is where the proliferating cell line leads to bone marrow fibrosis, where the bone marrow is replaced by scar tissue.

This is in response to cytokines released from the proliferating cells.

...